S273: LONG-TERM ERYTHROID RESPONSE DATA FROM PATIENTS (PTS) WITH NON-TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA (NTDT) RECEIVING LUSPATERCEPT IN THE BEYOND TRIAL

Liknande verk

• Luspatercept for transfusion-dependent β-thalassemia: time to get real
  av: Khaled M. Musallam, et al.
  Utgiven: (2023-08-01)
• Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy
  av: Musallam KM, et al.
  Utgiven: (2023-05-01)
• Efficacy and safety of luspatercept in non–transfusion-dependent β-thalassemia: long-term results from the BEYOND study
  av: Ali T. Taher, et al.
  Utgiven: (2025-12-01)
• ENERGIZE: A GLOBAL PHASE 3 STUDY OF MITAPIVAT DEMONSTRATING EFFICACY AND SAFETY IN ADULTS WITH ALPHA- OR BETA-NON–TRANSFUSION-DEPENDENT THALASSEMIA
  av: AT Taher, et al.
  Utgiven: (2024-10-01)
• IMPROVEMENTS IN FATIGUE AND 6-MINUTE WALK TEST IN ADULTS WITH ALPHA- OR BETA-NON–TRANSFUSION-DEPENDENT THALASSEMIA: THE PHASE 3 ENERGIZE TRIAL OF MITAPIVAT
  av: KH Kuo, et al.
  Utgiven: (2024-10-01)